Drug Dose Adjustment in Dialysis Patients Admitted in Clinics Other Than Internal Medicine

Yalcin Solak, Zeynep Biyik, Abduzhappar Gaipov, Mehmet Kayrak, Hilal Ciray, Ahmet Cizmecioglu, Halil Zeki Tonbul, Suleyman Turk

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Many drugs that are administered during hospitalization are metabolized or excreted through kidneys, consequently require dosage adjustment. We aimed to investigate inappropriate prescription of drugs requiring renal dose adjustment (RDA) in various surgical and medical inpatient clinics. We retrospectively determined dialysis patients hospitalized between January 2007 and December 2010. Inpatient clinics, including cardiology, pulmonary medicine, neurology, infectious diseases (medical clinics) and cardiovascular surgery, orthopedics, general surgery, obstetrics and gynecology, and neurosurgery (surgical clinics), were screened via electronic database. Total and RDA medications were determined. RDA drugs correctly adjusted to creatinine clearance were labeled as RDA-A (appropriate), otherwise as RDA-I (inappropriate). Renal doses of RDA medications were based on the "American College of Physicians Drug Prescribing in Renal Failure, fifth Edition." Two hundred seventeen hospitalization records of 172 dialysis patients (92 men and 80 women) were included in the analysis. Mean age of patients was 59.4 ± 14.6 years, and the mean hospitalization duration was 8.5 ± 7.8 days. In total, 247 (84.3%, percentage in drugs requiring dose adjustment) and 175 (46.2%) drugs have been inadequately dosed in surgical and medical clinics, respectively. The percentage of patients to whom at least 1 RDA-I drug was ordered was 92% and 91.4% for surgical and medical clinics, respectively (P > 0.05). Nephrology consultation numbers were 8 (7.1%) in surgical and 32 (30.4%) in medical clinics. The most common RDA-I drugs were aspirin and famotidine. A significant portion of RDA drugs was ordered inappropriately both in surgical and medical clinics. Nephrology consultation rate was very low. Measures to increase physician awareness are required to improve results.

Original languageEnglish (US)
Pages (from-to)e68-e73
JournalAmerican Journal of Therapeutics
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Internal Medicine
Dialysis
Kidney
Pharmaceutical Preparations
Hospitalization
Nephrology
Inpatients
Referral and Consultation
Inappropriate Prescribing
Famotidine
Physicians
Drug Prescriptions
Pulmonary Medicine
Prescription Drugs
Neurosurgery
Neurology
Cardiology
Gynecology
Aspirin
Obstetrics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Drug Dose Adjustment in Dialysis Patients Admitted in Clinics Other Than Internal Medicine. / Solak, Yalcin; Biyik, Zeynep; Gaipov, Abduzhappar; Kayrak, Mehmet; Ciray, Hilal; Cizmecioglu, Ahmet; Tonbul, Halil Zeki; Turk, Suleyman.

In: American Journal of Therapeutics, Vol. 23, No. 1, 01.01.2016, p. e68-e73.

Research output: Contribution to journalArticle

Solak, Y, Biyik, Z, Gaipov, A, Kayrak, M, Ciray, H, Cizmecioglu, A, Tonbul, HZ & Turk, S 2016, 'Drug Dose Adjustment in Dialysis Patients Admitted in Clinics Other Than Internal Medicine', American Journal of Therapeutics, vol. 23, no. 1, pp. e68-e73. https://doi.org/10.1097/MJT.0b013e3182a4ef81
Solak, Yalcin ; Biyik, Zeynep ; Gaipov, Abduzhappar ; Kayrak, Mehmet ; Ciray, Hilal ; Cizmecioglu, Ahmet ; Tonbul, Halil Zeki ; Turk, Suleyman. / Drug Dose Adjustment in Dialysis Patients Admitted in Clinics Other Than Internal Medicine. In: American Journal of Therapeutics. 2016 ; Vol. 23, No. 1. pp. e68-e73.
@article{15d7259b00724f63944f33ca539c179f,
title = "Drug Dose Adjustment in Dialysis Patients Admitted in Clinics Other Than Internal Medicine",
abstract = "Many drugs that are administered during hospitalization are metabolized or excreted through kidneys, consequently require dosage adjustment. We aimed to investigate inappropriate prescription of drugs requiring renal dose adjustment (RDA) in various surgical and medical inpatient clinics. We retrospectively determined dialysis patients hospitalized between January 2007 and December 2010. Inpatient clinics, including cardiology, pulmonary medicine, neurology, infectious diseases (medical clinics) and cardiovascular surgery, orthopedics, general surgery, obstetrics and gynecology, and neurosurgery (surgical clinics), were screened via electronic database. Total and RDA medications were determined. RDA drugs correctly adjusted to creatinine clearance were labeled as RDA-A (appropriate), otherwise as RDA-I (inappropriate). Renal doses of RDA medications were based on the {"}American College of Physicians Drug Prescribing in Renal Failure, fifth Edition.{"} Two hundred seventeen hospitalization records of 172 dialysis patients (92 men and 80 women) were included in the analysis. Mean age of patients was 59.4 ± 14.6 years, and the mean hospitalization duration was 8.5 ± 7.8 days. In total, 247 (84.3{\%}, percentage in drugs requiring dose adjustment) and 175 (46.2{\%}) drugs have been inadequately dosed in surgical and medical clinics, respectively. The percentage of patients to whom at least 1 RDA-I drug was ordered was 92{\%} and 91.4{\%} for surgical and medical clinics, respectively (P > 0.05). Nephrology consultation numbers were 8 (7.1{\%}) in surgical and 32 (30.4{\%}) in medical clinics. The most common RDA-I drugs were aspirin and famotidine. A significant portion of RDA drugs was ordered inappropriately both in surgical and medical clinics. Nephrology consultation rate was very low. Measures to increase physician awareness are required to improve results.",
author = "Yalcin Solak and Zeynep Biyik and Abduzhappar Gaipov and Mehmet Kayrak and Hilal Ciray and Ahmet Cizmecioglu and Tonbul, {Halil Zeki} and Suleyman Turk",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/MJT.0b013e3182a4ef81",
language = "English (US)",
volume = "23",
pages = "e68--e73",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Drug Dose Adjustment in Dialysis Patients Admitted in Clinics Other Than Internal Medicine

AU - Solak, Yalcin

AU - Biyik, Zeynep

AU - Gaipov, Abduzhappar

AU - Kayrak, Mehmet

AU - Ciray, Hilal

AU - Cizmecioglu, Ahmet

AU - Tonbul, Halil Zeki

AU - Turk, Suleyman

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Many drugs that are administered during hospitalization are metabolized or excreted through kidneys, consequently require dosage adjustment. We aimed to investigate inappropriate prescription of drugs requiring renal dose adjustment (RDA) in various surgical and medical inpatient clinics. We retrospectively determined dialysis patients hospitalized between January 2007 and December 2010. Inpatient clinics, including cardiology, pulmonary medicine, neurology, infectious diseases (medical clinics) and cardiovascular surgery, orthopedics, general surgery, obstetrics and gynecology, and neurosurgery (surgical clinics), were screened via electronic database. Total and RDA medications were determined. RDA drugs correctly adjusted to creatinine clearance were labeled as RDA-A (appropriate), otherwise as RDA-I (inappropriate). Renal doses of RDA medications were based on the "American College of Physicians Drug Prescribing in Renal Failure, fifth Edition." Two hundred seventeen hospitalization records of 172 dialysis patients (92 men and 80 women) were included in the analysis. Mean age of patients was 59.4 ± 14.6 years, and the mean hospitalization duration was 8.5 ± 7.8 days. In total, 247 (84.3%, percentage in drugs requiring dose adjustment) and 175 (46.2%) drugs have been inadequately dosed in surgical and medical clinics, respectively. The percentage of patients to whom at least 1 RDA-I drug was ordered was 92% and 91.4% for surgical and medical clinics, respectively (P > 0.05). Nephrology consultation numbers were 8 (7.1%) in surgical and 32 (30.4%) in medical clinics. The most common RDA-I drugs were aspirin and famotidine. A significant portion of RDA drugs was ordered inappropriately both in surgical and medical clinics. Nephrology consultation rate was very low. Measures to increase physician awareness are required to improve results.

AB - Many drugs that are administered during hospitalization are metabolized or excreted through kidneys, consequently require dosage adjustment. We aimed to investigate inappropriate prescription of drugs requiring renal dose adjustment (RDA) in various surgical and medical inpatient clinics. We retrospectively determined dialysis patients hospitalized between January 2007 and December 2010. Inpatient clinics, including cardiology, pulmonary medicine, neurology, infectious diseases (medical clinics) and cardiovascular surgery, orthopedics, general surgery, obstetrics and gynecology, and neurosurgery (surgical clinics), were screened via electronic database. Total and RDA medications were determined. RDA drugs correctly adjusted to creatinine clearance were labeled as RDA-A (appropriate), otherwise as RDA-I (inappropriate). Renal doses of RDA medications were based on the "American College of Physicians Drug Prescribing in Renal Failure, fifth Edition." Two hundred seventeen hospitalization records of 172 dialysis patients (92 men and 80 women) were included in the analysis. Mean age of patients was 59.4 ± 14.6 years, and the mean hospitalization duration was 8.5 ± 7.8 days. In total, 247 (84.3%, percentage in drugs requiring dose adjustment) and 175 (46.2%) drugs have been inadequately dosed in surgical and medical clinics, respectively. The percentage of patients to whom at least 1 RDA-I drug was ordered was 92% and 91.4% for surgical and medical clinics, respectively (P > 0.05). Nephrology consultation numbers were 8 (7.1%) in surgical and 32 (30.4%) in medical clinics. The most common RDA-I drugs were aspirin and famotidine. A significant portion of RDA drugs was ordered inappropriately both in surgical and medical clinics. Nephrology consultation rate was very low. Measures to increase physician awareness are required to improve results.

UR - http://www.scopus.com/inward/record.url?scp=84955632555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955632555&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3182a4ef81

DO - 10.1097/MJT.0b013e3182a4ef81

M3 - Article

VL - 23

SP - e68-e73

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 1

ER -